Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, SCTIMST, Thiruvananthapuram, Kerala, 695011, India.
Achutha Menon Center for Health Science Studies, Thiruvananthapuram, Kerala, 695011, India.
BMC Pediatr. 2023 Sep 7;23(1):446. doi: 10.1186/s12887-023-04255-z.
Although much research has been done on adult hypertrophic cardiomyopathy, data on pediatric hypertrophic cardiomyopathy is still limited.
The study enrolled all patients with cardiomyopathy who presented to us between 1990 to 2020 and were younger than 18 yrs. During the thirty-year study period, we identified 233 cases of pediatric cardiomyopathy. Sixty-three cases (27%) had hypertrophic cardiomyopathy. Out of the 63 HCM cases, 12% presented in the neonatal period and 37% presented in the first year of life. The median age of presentation was 7 yrs (Range 0.1-18 yrs). Sixteen patients had proven syndromic, metabolic, or genetic disease (25%). LV outflow obstruction was present in 30 patients (47%). Noonan syndrome was present in 9 of the 63 patients (14%). Dyspnea on exertion was the most common mode of presentation. Cardiac MRI was done in 28 patients, out of which 17 had late gadolinium enhancement (LGE). Mid myocardial enhancement was the most common pattern. Four patients had LGE of more than 15%. Over a mean follow-up period of 5.6 years (0.1-30 years), twenty-one were lost to follow-up (33%). Among the patients whose outcome was known, eleven died (26%), and thirty-one (73%) were alive. The 5-year survival rate of HCM patients was 82%, and the 10-year survival rate was 78%. Seven died of sudden cardiac death, three from heart failure, and one from ventricular arrhythmias. Sustained ventricular arrhythmias were seen in three patients and atrial arrhythmias in two. First-degree AV block was seen in 10 patients (15%) and bundle branch blocks (BBB) in five (8%). Eight patients required ICD or transplant (12.7%). Two patients underwent ICD for primary prevention, and one underwent PPI for distal AV conduction disease. Among the various clinical, echocardiographic, and radiological risk factors studied, only consanguinity showed a trend towards higher events of death or ventricular arrhythmias (P-value 0.08).
More than one-third of our HCM cohort presented in infancy. LV outflow tract obstruction is common (47%). Mid myocardial enhancement was the most common pattern of late gadolinium enhancement. SCD was the most common cause of death. The outcome in our HCM cohort is good and similar to other population cohorts. Only Consanguinity showed a trend towards higher events of death or ventricular arrhythmias.
尽管已有大量研究针对成人肥厚型心肌病,但儿科肥厚型心肌病的数据仍有限。
本研究纳入了 1990 年至 2020 年间就诊的所有年龄小于 18 岁的心肌病患者。在三十年的研究期间,我们共确定了 233 例儿科心肌病患者,其中 63 例(27%)为肥厚型心肌病。这 63 例 HCM 患者中,12%在新生儿期发病,37%在 1 岁以内发病。中位发病年龄为 7 岁(0.1-18 岁)。16 例患者存在已证实的综合征、代谢或遗传疾病(25%)。30 例(47%)存在左心室流出道梗阻。9 例(14%)患者存在努南综合征。呼吸困难是最常见的发病模式。28 例行心脏 MRI 检查,其中 17 例存在晚期钆增强(LGE)。中心肌强化是最常见的模式。4 例患者 LGE 超过 15%。在平均 5.6 年(0.1-30 年)的随访期间,21 例失访(33%)。已知结局的患者中,11 例死亡(26%),31 例存活(73%)。HCM 患者的 5 年生存率为 82%,10 年生存率为 78%。7 例患者死于心源性猝死,3 例死于心力衰竭,1 例死于室性心律失常。3 例患者出现持续性室性心律失常,2 例患者出现房性心律失常。10 例(15%)患者存在一度房室传导阻滞,5 例(8%)患者存在束支传导阻滞。8 例患者需要植入 ICD 或心脏移植(12.7%)。2 例患者因一级预防植入 ICD,1 例患者因远端房室传导疾病植入起搏器。在研究的各种临床、超声心动图和影像学危险因素中,仅近亲结婚显示出与死亡或室性心律失常事件更高的趋势(P 值为 0.08)。
我们 HCM 队列中超过三分之一的患者在婴儿期发病。左心室流出道梗阻很常见(47%)。中心肌强化是晚期钆增强最常见的模式。心源性猝死是最常见的死亡原因。我们的 HCM 队列的结局良好,与其他人群队列相似。仅近亲结婚显示出与死亡或室性心律失常事件更高的趋势。